Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 2 Published - 14:00 UTC    08:00 EST    30-March-2001      
Issue 89 Next Update - 14:00 UTC 08:00 EST    31-March-2001      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya Today In Vidyyasm

Vidyya Medical News Service For 30-March-2001:

The following stories appear in full on Today's Vidyya Medical News Service Web site.

The injectable anesthesia drug Raplon (rapacuronium bromide) is being voluntarily withdrawn from the market after its manufacturer received reports indicating that the drug may be associated with bronchospasm - a mild to severe inability to breathe normally that can lead to permanent injury or death. Five deaths, reported to the manufacturer, occurred during the administration of Raplon.

For more information: Injectable Anesthesia Drug Being Withdrawn From Market

Healthcare professionals are notified about the need for dosage adjustments for Pepcid for patients with moderate renal insufficiency [creatinine clearance < 50ml/minute] . The previous labeling recommended adjustments for severe insufficiency only [creatinine clearance < 10ml/minute]. This information is particularly important for healthcare professionals, particularly those caring for elderly patients in nursing home settings.

For more information: Safety Notice: Pepcid Labeling Changes Vidyya understands the need of health professionals to have access to up-to-date prescribing information and we are pleased to provide the updated Pepcid prescribing info for you. Our readers will find the changes highlighted in yellow for easy reading. We hope you find this information useful to your health practice.

For more information: Copy Of Label Changes - Pepcid

Aventis Pharmaceuticals is initiating a voluntary recall of Taxotere® (docetaxel) for Injection Concentrate 20-mg active and diluent vials. The lot numbers for this recall are: 0P273 (active) which was packaged together with diluent vials with the following lot numbers 0T446 (diluent) or 0T449 (diluent).

For more information: Voluntary Drug Recall - Taxotere ® (docetaxel) For Injection Concentrate 20-mg

A new type of 3-D mammography, based on an imaging system originally developed to pinpoint tooth decay, has received approval from the US Food and Drug Administration and will likely be ready for market soon in the United States.

For more information: 3-D Mammography Device to See Hidden Tumors Is Approved for US Market

Today's Vidyya articles are:

As always, we hope you enjoy the issue.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 
Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.